TW202214233A - 可做為tlr9抑制劑之經取代雜芳基化合物 - Google Patents

可做為tlr9抑制劑之經取代雜芳基化合物 Download PDF

Info

Publication number
TW202214233A
TW202214233A TW110130428A TW110130428A TW202214233A TW 202214233 A TW202214233 A TW 202214233A TW 110130428 A TW110130428 A TW 110130428A TW 110130428 A TW110130428 A TW 110130428A TW 202214233 A TW202214233 A TW 202214233A
Authority
TW
Taiwan
Prior art keywords
phenyl
pyrrolo
dimethyl
methylsulfonyl
pyridine
Prior art date
Application number
TW110130428A
Other languages
English (en)
Chinese (zh)
Inventor
春健 劉
藍恩 艾莉西亞 里圭洛
Original Assignee
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW202214233A publication Critical patent/TW202214233A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW110130428A 2020-08-19 2021-08-18 可做為tlr9抑制劑之經取代雜芳基化合物 TW202214233A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067465P 2020-08-19 2020-08-19
US63/067,465 2020-08-19

Publications (1)

Publication Number Publication Date
TW202214233A true TW202214233A (zh) 2022-04-16

Family

ID=77711459

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110130428A TW202214233A (zh) 2020-08-19 2021-08-18 可做為tlr9抑制劑之經取代雜芳基化合物

Country Status (14)

Country Link
US (1) US12590091B2 (enExample)
EP (1) EP4200298B1 (enExample)
JP (1) JP2023538608A (enExample)
KR (1) KR20230053646A (enExample)
CN (1) CN115867549A (enExample)
AR (1) AR123285A1 (enExample)
AU (1) AU2021328577A1 (enExample)
BR (1) BR112023002646A2 (enExample)
CA (1) CA3189826A1 (enExample)
ES (1) ES3034264T3 (enExample)
IL (1) IL300643A (enExample)
MX (1) MX2023001929A (enExample)
TW (1) TW202214233A (enExample)
WO (1) WO2022040267A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
EP4479135A1 (en) * 2022-02-18 2024-12-25 Bristol-Myers Squibb Company Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
KR20250109202A (ko) * 2022-11-10 2025-07-16 브리스톨-마이어스 스큅 컴퍼니 Tlr9의 억제제로서 유용한 치환된 벤즈이미다졸 화합물
CN120152957A (zh) * 2022-11-10 2025-06-13 百时美施贵宝公司 用作tlr9抑制剂的经取代的喹诺酮
WO2024163380A1 (en) * 2023-01-31 2024-08-08 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9
TW202504599A (zh) 2023-06-30 2025-02-01 美商必治妥美雅史谷比公司 Kras抑制劑
WO2026039512A1 (en) 2024-08-14 2026-02-19 Bristol-Myers Squibb Company Kras inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
US20130158049A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
EP3538513A1 (en) 2016-11-11 2019-09-18 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
US11399542B2 (en) 2017-07-05 2022-08-02 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
SG11202005704RA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes

Also Published As

Publication number Publication date
US12590091B2 (en) 2026-03-31
WO2022040267A1 (en) 2022-02-24
BR112023002646A2 (pt) 2023-04-04
KR20230053646A (ko) 2023-04-21
CN115867549A (zh) 2023-03-28
US20230312565A1 (en) 2023-10-05
AU2021328577A1 (en) 2023-03-23
CA3189826A1 (en) 2022-02-24
AR123285A1 (es) 2022-11-16
EP4200298B1 (en) 2025-05-21
ES3034264T3 (en) 2025-08-14
IL300643A (en) 2023-04-01
EP4200298A1 (en) 2023-06-28
JP2023538608A (ja) 2023-09-08
MX2023001929A (es) 2023-03-09

Similar Documents

Publication Publication Date Title
EP4200298B1 (en) 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
EP4200015B1 (en) Substituted heteroaryl compounds useful as inhibitors of tlr9
KR20230053645A (ko) 섬유증의 치료를 위한 tlr9 억제제로서의 1h-벤조[d]이미다졸 유도체
JP7813775B2 (ja) 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体
EA050843B1 (ru) Замещенные гетероарильные соединения, пригодные для применения в качестве ингибиторов tlr9
AU2023221404A1 (en) Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
WO2023159154A9 (en) Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
EA047759B1 (ru) Замещенные гетероарильные соединения, пригодные для применения в качестве ингибиторов tlr9
WO2024102884A1 (en) Substituted quinolone compounds useful as inhibitors of tlr9
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9